Anti-Anxiety

Klonopin (Clonazepam)

* For illustration purpose only

Klonopin (Clonazepam)

Short description

Learn more

Klonopin (Clonazepam) 2mg (UK) 30 pills 30 pills

90,563.23 HUF

Klonopin (Clonazepam) 2mg (UK) 60 pills 60 pills

132,361.64 HUF

Klonopin (Clonazepam) 2mg (UK) 90 pills 90 pills

173,793.40 HUF

Klonopin (Clonazepam) 2mg (UK) 120 pills 120 pills

215,591.81 HUF

Klonopin (Clonazepam) 2mg (UK) 180 pills 180 pills

299,188.63 HUF

Klonopin (Clonazepam) 2mg (UK) 240 pills 240 pills

382,418.80 HUF

Klonopin (Clonazepam) 2mg (UK) 270 pills 270 pills

424,217.22 HUF

Klonopin (Clonazepam) 2mg (UK) 360 pills 360 pills

549,245.80 HUF

Klonopin (Clonazepam) 2mg (EU) 30 pills 30 pills

67,830.76 HUF

Popular Klonopin (Clonazepam) 2mg (EU) 60 pills 60 pills

92,396.49 HUF

Klonopin (Clonazepam) 2mg (EU) 90 pills 90 pills

116,962.22 HUF

Klonopin (Clonazepam) 2mg (EU) 120 pills 120 pills

141,527.96 HUF

Klonopin (Clonazepam) 2mg (EU) 180 pills 180 pills

191,026.08 HUF

Klonopin (Clonazepam) 2mg (EU) 240 pills 240 pills

240,157.54 HUF

Klonopin (Clonazepam) 2mg (EU) 270 pills 270 pills

264,723.28 HUF

Klonopin (Clonazepam) 2mg (EU) 360 pills 360 pills

338,420.48 HUF

90563.23

In Stock

added to cart

Shipping

avrg. 5-9 days

Guaranteed delivery time 16 days

Guaranteed delivery time 16 days

Dosages mentioned (EU), are shipped inside Europe and guarantee faster time in delivery.
Payment
Upgrade and save. Add worth of items to cart and get free shipping

Shipping free of charge.

73330.55 HUF

Free shipping for orders more than €200

Discreet packaging. Secure and confidential

100% moneyback guarantee

No prescription required

Klonopin (Clonazepam)

Commercial Name: Klonopin, Rivotril

Active Ingredient: Clonazepam

Production form: pills

Utilization: Anti-Anxiety

Available Dosage: 2mg

Regarding Shipping: Products with dosages mentioned (EU), are shipped inside Europe and garantuee faster time in delivery.

Klonopin is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, Klonopin may be useful.

SIDE EFFECTS

The adverse experiences for Klonopin are provided separately for patients with seizure disorders and panic disorder.

Seizure Disorders

The most frequently occurring side effects of Klonopin are referable to CNS depression. Experience in treatment of seizures has shown that drowsiness has occurred in approximately 50% of patients and ataxia in approximately 30%. In some cases, these may diminish with time; behaviour problems have been noted in approximately 25% of patients. Others, listed by system, including those identified during postapproval use of Klonopin are:

• Cardiovascular: Palpitations

• Dermatologic: Hair loss, hirsutism, skin rash, ankle and facial oedema

• Gastrointestinal: Anorexia, coated tongue, constipation, diarrhoea, dry mouth, encopresis, gastritis, increased appetite, nausea, sore gums

• Genitourinary: Dysuria, enuresis, nocturia, urinary retention

• Hematopoietic: Anemia, leukopenia, thrombocytopenia, eosinophilia

• Hepatic: Hepatomegaly, transient elevations of serum transaminases and alkaline phosphatase

• Musculoskeletal: Muscle weakness, pains

• Miscellaneous: Dehydration, general deterioration, fever, lymphadenopathy, weight loss or gain

• Neurologic: Abnormal eye movements, aphonia, choreiform movements, coma, diplopia dysarthria, dysdiadochokinesis, ‘‘glassy-eyed’’ appearance, headache, hemiparesis, hypotonia, nystagmus, respiratory depression, slurred speech, tremor, vertigo

• Psychiatric: Confusion, depression, amnesia, hysteria, increased libido, insomnia, psychosis (the behaviour effects are more likely to occur in patients with a history of psychiatric disturbances).

• The following paradoxical reactions have been observed: irritability, aggression, agitation, nervousness, hostility, anxiety, sleep disturbances, nightmares, abnormal dreams, hallucinations.

• Respiratory: Chest congestion, rhinorrhea, shortness of breath, hypersecretion in upper respiratory passages

Panic Disorder

Adverse events during exposure to Klonopin were obtained by spontaneous report and recorded by clinical investigators using the terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events into a smaller number of standardized event categories. In the tables and tabulations that follow, CIGY dictionary terminology has been used to classify reported adverse events, except in certain cases in which redundant terms were collapsed into more meaningful terms, as noted below.

The stated frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed. An event was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.

• Adverse Findings Observed In Short-Term, Placebo-Controlled Trials

• Adverse Events Associated With Discontinuation Of Treatment

• Overall, the incidence of discontinuation due to adverse events was 17% in Klonopin compared to 9% for placebo in the combined data of two 6- to 9-week trials.

Add Review

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, to

First Name

Last Name

Age

Title

Review

Effectiveness
Ease of use/handling
Price-performance ratio